Gene therapy trial offers hope for second eye treatment in rare vision disorder
NCT ID NCT06646289
Summary
This study is testing the safety of a gene therapy treatment for the second eye in people with X-linked retinitis pigmentosa, a rare inherited condition that causes progressive vision loss. The trial includes 24 adults and children who previously received the same gene therapy in their first eye. Researchers will monitor for side effects and check if vision improves or stabilizes in the treated eye.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for X-LINKED RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, 02114, United States
-
Moorfields Eye Hospital
London, EC1V 2PD, United Kingdom
-
University of Michigan Kellogg Eye Center
Ann Arbor, Michigan, 48105, United States
Conditions
Explore the condition pages connected to this study.